Aardvark Therapeutics (AARD) News Today $11.29 -0.48 (-4.08%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Forecasts AARD FY2026 EarningsAardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Aardvark Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per shaJune 10 at 9:46 AM | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Raised to "Hold" at Wall Street ZenWall Street Zen raised Aardvark Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday.June 7, 2025 | marketbeat.comBiotech IPO Slump Seen Dragging Into 2026 as Returns DisappointMay 27, 2025 | msn.comEquities Analysts Set Expectations for AARD FY2025 EarningsAardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Aardvark Therapeutics in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company willMay 21, 2025 | marketbeat.comAardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal FunctionsMay 19, 2025 | globenewswire.comCantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN)May 18, 2025 | theglobeandmail.comAardvark Therapeutics Reports Phase 3 HERO Trial Progress for ARD-101 in Prader-Willi Syndrome and Financial Results for Q1 2025May 16, 2025 | nasdaq.comAardvark Therapeutics, Inc.: Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 15, 2025 | finanznachrichten.deAardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | globenewswire.comAardvark Therapeutics to Present at Upcoming Investor Conferences in MayMay 7, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Organon (OGN) and Cardinal Health (CAH)May 7, 2025 | theglobeandmail.comAardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% - What's Next?Aardvark Therapeutics (NASDAQ:AARD) Stock Price Up 7.6% - Here's What HappenedApril 25, 2025 | marketbeat.comAardvark Therapeutics, Inc. Common Stock (AARD)April 18, 2025 | finance.yahoo.comAardvark Therapeutics (NASDAQ:AARD) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $21.00 target price on shares of Aardvark Therapeutics in a research report on Tuesday.April 3, 2025 | marketbeat.comAardvark Therapeutics' (AARD) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday.April 2, 2025 | marketbeat.comAARD Aardvark Therapeutics, Inc.April 2, 2025 | seekingalpha.comRBC Capital Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)April 2, 2025 | markets.businessinsider.comAardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business HighlightsMarch 31, 2025 | globenewswire.comAardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00 at Bank of AmericaBank of America boosted their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Thursday.March 28, 2025 | marketbeat.comDrugmaker Soleno Soars on Approval to Treat Never Ending HungerMarch 27, 2025 | finance.yahoo.comAardvark Therapeutics price target raised to $26 from $22 at BofAMarch 27, 2025 | markets.businessinsider.comSoleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses LowerMarch 27, 2025 | msn.comSoleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark HigherMarch 27, 2025 | msn.comAardvark Therapeutics Inc Share Price (AARD.US)March 21, 2025 | lse.co.ukAardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comAardvark Therapeutics initiated with an Overweight at Cantor FitzgeraldMarch 12, 2025 | markets.businessinsider.comAardvark Therapeutics initiated with an Outperform at RBC CapitalMarch 11, 2025 | markets.businessinsider.comAardvark Therapeutics initiated with a Buy at BofAMarch 11, 2025 | markets.businessinsider.comBiotechs Highlight 6 Stocks Insiders Are Buying NowFebruary 23, 2025 | 247wallst.comAardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Purchases $160,000.00 in StockFebruary 20, 2025 | insidertrades.comU.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO WeekFebruary 15, 2025 | seekingalpha.com Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address AARD Media Mentions By Week AARD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AARD News Sentiment▼1.080.87▲Average Medical News Sentiment AARD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AARD Articles This Week▼62▲AARD Articles Average Week Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SYRE News CVAC News AKBA News PAHC News SNDX News NRIX News COLL News AVDL News QURE News NAGE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AARD) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AARD Stock Free AARD Stock Alerts